NEW YORK (GenomeWeb News) – Verastem said today that Laboratory Corporation of America will help it validate biomarkers that could be used to develop a companion diagnostic for a Verastem drug candidate, the focal adhesion inhibitor VS-6063.

The biomarkers will be used in clinical studies in ovarian cancer and mesothelioma, including a potentially pivotal study of VS-6063 in mesothelioma expected to commence later this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.